Additional file 8. Sequencing statistics of the HER2 heterogeneous breast cancer subjected to whole exome sequencing and to targeted capture massively parallel sequencing using a platform containing baits targeting all exons of 273 genes.

Case ID	Sample	Total Reads	Mean Coverage	PCT Target Bases 2X	PCT Target Bases 10X		PCT Target Bases 30X			PCT Target Bases 100X	Sequencing platform
T1	HER2-positive	95,809,294	540.39	99.20%	98.96%	98.83%	98.71%	98.44%	97.76%	86.72%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T1	HER2-negative	108,792,619	776.81	99.18%	98.94%	98.78%	98.62%	98.19%	97.34%	89.39%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T1	Normal	75,231,689	692.01	99.20%	98.91%	98.75%	98.39%	97.38%	95.98%	86.92%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T3	HER2-positive	67,513,517	292.89	98.72%	98.26%	97.82%	96.34%	91.71%	83.20%	46.10%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T3	HER2-negative	96,504,449	450.43	98.91%	98.50%	98.26%	98.03%	97.44%	95.74%	65.57%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T3	Normal	56,107,533	305.53	98.85%	98.45%	98.18%	97.80%	96.42%	92.51%	52.42%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T4	HER2-positive	50,241,782	165.42	98.63%	98.22%	97.95%	97.70%	97.47%	97.23%	82.24%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T4	HER2-negative	47,040,127	120.99	98.59%	98.05%	97.64%	97.19%	95.85%	92.31%	43.49%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T4	Normal	40,260,973	135.00	98.70%	98.25%	97.94%	97.72%	97.52%	97.16%	71.66%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T8	HER2-positive	59,122,043	243.85	98.88%	98.44%	98.24%	98.09%	97.95%	97.83%	97.13%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T8	HER2-negative	93,392,969	388.46	98.97%	98.59%	98.42%	98.27%	98.16%	98.06%	96.99%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T8	Normal	48,827,302	247.47	98.90%	98.47%	98.25%	98.09%	97.96%	97.84%	95.79%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T9	HER2-positive	72,021,110	298.05	98.85%	98.54%	98.32%	98.17%	97.99%	97.51%	81.03%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T9	HER2-negative	61,174,704	306.75	98.87%	98.54%	98.38%	98.26%	98.15%	98.06%	97.46%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T9	Normal	82,512,645	564.75	99.00%	98.71%	98.56%	98.45%	98.37%	98.30%	97.95%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T12	HER2-positive	47,202,108	226.67	98.90%	98.50%	98.26%	98.07%	97.86%	97.63%	94.88%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T12	HER2-negative	50,965,403	200.18	98.92%	98.47%	98.19%	97.89%	97.57%	97.20%	91.95%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T12	Normal	64,245,194	317.73	98.94%	98.58%	98.37%	98.18%	97.95%	97.78%	96.26%	Targeted sequencing of 273 genes frequently mutated in breast cancer
T6	HER2-positive	71,246,443	56.78	95.54%	88.67%	79.27%	67.04%	54.23%	42.82%	13.03%	Whole exome sequencing
T6	HER2-negative	69,076,811	57.96	93.73%	84.78%	74.54%	63.67%	53.11%	43.52%	14.95%	Whole exome sequencing
T6	Normal	106,077,251	85.01	95.13%	88.39%	82.34%	76.30%	69.69%	62.61%	30.54%	Whole exome sequencing
T11	HER2-positive	99,608,421	80.70	94.88%	87.97%	81.70%	75.21%	68.04%	60.29%	27.63%	Whole exome sequencing
T11	HER2-negative	67,667,683	55.67	94.67%	86.42%	76.59%	65.49%	54.13%	43.66%	13.41%	Whole exome sequencing
T11	Normal	61,190,636	50.29	94.56%	85.99%	75.55%	63.16%	50.47%	39.07%	10.10%	Whole exome sequencing
T12	HER2-positive	323,195,245	254.25	93.71%	91.29%	89.20%	87.06%	84.92%	82.80%	72.21%	Whole exome sequencing
T12	HER2-negative	314,364,349	248.59	93.63%	91.14%	88.97%	86.76%	84.54%	82.34%	71.30%	Whole exome sequencing
T12	Normal	131,167,048	114.97	92.58%	88.86%	84.38%	79.96%	75.53%	71.06%	47.95%	Whole exome sequencing

PCT, percentage